Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naveen S Basappa

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 2, 2020
Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information systemRyan Sun, Rodney H Breau, Ranjeeta Mallick, et al.
European Urology|May 5, 2020
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell CarcinomaBimal Bhindi, Jeffrey Graham, J Connor Wells, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
European Urology Oncology|January 1, 2025
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium AnalysisMehul Gupta, Connor Wells, Meredith M Regan, et al.
European Urology Oncology|January 20, 2026
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Jeffrey Graham, David Maj, et al.
The Oncologist|August 4, 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell CarcinomaManon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, et al.
European Urology Oncology|November 1, 2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Matthew S Ernst, Vishal Navani, et al.
JAMA Network Open|June 10, 2022
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell CarcinomaVishal Navani, Matthew Ernst, J Connor Wells, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
BJU International|December 4, 2024
Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?Mustafa Soytas, Alice Dragomir, Ghady Bou-Nehme Sawaya, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 2, 2020
Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information systemRyan Sun, Rodney H Breau, Ranjeeta Mallick, et al.
European Urology|May 5, 2020
Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell CarcinomaBimal Bhindi, Jeffrey Graham, J Connor Wells, et al.
European Journal of Cancer (Oxford, England : 1990)|May 11, 2021
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trialsChun L Gan, Igor Stukalin, Daniel E Meyers, et al.
European Urology Oncology|January 1, 2025
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium AnalysisMehul Gupta, Connor Wells, Meredith M Regan, et al.
European Urology Oncology|January 20, 2026
Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Jeffrey Graham, David Maj, et al.
The Oncologist|August 4, 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell CarcinomaManon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, et al.
European Urology Oncology|November 1, 2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Matthew S Ernst, Vishal Navani, et al.
JAMA Network Open|June 10, 2022
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell CarcinomaVishal Navani, Matthew Ernst, J Connor Wells, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
BJU International|December 4, 2024
Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?Mustafa Soytas, Alice Dragomir, Ghady Bou-Nehme Sawaya, et al.
Pageof 6